Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Jun;29(6):715–723. doi: 10.1111/j.1365-2125.1990.tb03693.x

Ketanserin pharmacokinetics in patients with renal failure.

J N Barendregt 1, A Van Peer 1, J G Van Der Hoeven 1, J C Van Oene 1, Y I Tjandra 1
PMCID: PMC1380174  PMID: 2378791

Abstract

1. The pharmacokinetics of ketanserin and its major metabolite ketanserin-ol were investigated after a single oral dose of 40 mg and after chronic oral administration of 20 or 40 mg twice daily for 10 days in 12 patients with chronic renal insufficiency of whom six were on intermittent haemodialysis. Plasma protein binding of ketanserin was measured in these 12 patients and in eight healthy volunteers. 2. In both dialysis and non-dialysis patients the terminal half-life of ketanserin (mean +/- s.d.) was prolonged compared with that reported previously for healthy volunteers (28 +/- 4 h vs 18 +/- 4 h). This may be explained by a lowered renal clearance of ketanserin-ol from which ketanserin is partly regenerated. 3. In patients with chronic renal insufficiency plasma ketanserin concentrations were similar to those found in healthy subjects after the same dose. Plasma ketanserin-ol concentrations were elevated, resulting in a raised AUC ratio of ketanserin-ol to ketanserin as compared with healthy individuals (7.3 +/- 4.0 vs 3.2 +/- 0.7). 4. Urinary excretion of ketanserin was negligible in both dialysis and non-dialysis patients, and ketanserin-ol excretion was markedly lowered. 5. The plasma protein binding of ketanserin was slightly reduced in comparison with healthy volunteers (93.7 +/- 1.0% vs 95.0 +/- 0.2%). 6. A dose regimen of 20 mg twice daily appeared to be well tolerated in spite of less plasma binding in renal failure.

Full text

PDF
715

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Hedner T., Persson B., Berglund G. Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension. Br J Clin Pharmacol. 1983 Aug;16(2):121–125. doi: 10.1111/j.1365-2125.1983.tb04974.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Heykants J., Michiels M., Woestenborghs R., Awouters F., Leysen J. E., Schuurkes J., Van Nueten J. M. Pharmacokinetic evaluation of the in vitro and in vivo pharmacological profile of the major metabolites of ketanserin in the rat. Arzneimittelforschung. 1988 Jun;38(6):785–788. [PubMed] [Google Scholar]
  3. Heykants J., Van Peer A., Woestenborghs R., Gould S., Mills J. Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration. Eur J Clin Pharmacol. 1986;31(3):343–350. doi: 10.1007/BF00981135. [DOI] [PubMed] [Google Scholar]
  4. Kurowski M. Bioavailability and pharmacokinetics of ketanserin in elderly subjects. Eur J Clin Pharmacol. 1985;28(4):411–417. doi: 10.1007/BF00544359. [DOI] [PubMed] [Google Scholar]
  5. Meuldermans W., Van Houdt J., Mostmans E., Knaeps F., Verluyten W., Heykants J. Plasma protein binding of ketanserin and its distribution in blood. Arzneimittelforschung. 1988 Jun;38(6):794–800. [PubMed] [Google Scholar]
  6. Okonkwo P. O., Reimann I. W., Woestenborghs R., Klotz U. High-performance liquid chromatographic assay with fluorometric detection of ketanserin, a new antihypertensive agent and serotonin S2 antagonist in human plasma, blood and urine. J Chromatogr. 1983 Feb 11;272(2):411–416. doi: 10.1016/s0378-4347(00)86149-6. [DOI] [PubMed] [Google Scholar]
  7. Persson B., Pettersson A., Hedner T. Pharmacokinetics of ketanserin in patients with essential hypertension. Eur J Clin Pharmacol. 1987;32(3):259–265. doi: 10.1007/BF00607573. [DOI] [PubMed] [Google Scholar]
  8. Reimann I. W., Okonkwo P. O., Klotz U. Pharmacokinetics of ketanserin in man. Eur J Clin Pharmacol. 1983;25(1):73–76. doi: 10.1007/BF00544018. [DOI] [PubMed] [Google Scholar]
  9. Trenk D., Mosler A., Kirch W., Meinertz T., Jähnchen E. Pharmacokinetics and pharmacodynamics of the 5-HT2 receptor antagonist ketanserin in man. J Cardiovasc Pharmacol. 1983 Nov-Dec;5(6):1034–1039. doi: 10.1097/00005344-198311000-00018. [DOI] [PubMed] [Google Scholar]
  10. Van Peer A., Woestenborghs R., Embrechts L., Heykants J. Pharmacokinetic approach to equilibrium between ketanserin and ketanserin-ol. Eur J Clin Pharmacol. 1986;31(3):339–342. doi: 10.1007/BF00981134. [DOI] [PubMed] [Google Scholar]
  11. Wenting G. J., Woittiez A. J., Man in't Veld A. J., Schalekamp M. A. 5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency. Hypertension. 1984 Jan-Feb;6(1):100–109. doi: 10.1161/01.hyp.6.1.100. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES